Long-Read vs Short-Read Sequencing: What Your $300 WGS Test Might Be Missing

When people compare whole genome sequencing providers, the conversation almost always centers on coverage depth — 30x versus 15x, mostly. That's a meaningful number, but it's answering the wrong question if what you actually care about is completeness. The more consequential technical distinction, and the one almost nobody outside of genomics actually asks about, is whether a test uses short-read or long-read sequencing — because they don't just differ in speed or cost. They literally see different parts of your genome.

What Short-Read Sequencing Does Well

Short-read platforms — Illumina technology, used by the overwhelming majority of consumer and clinical WGS providers — break DNA into small fragments, typically 150-300 base pairs long, and sequence millions of them in parallel with extremely low error rates, often around 0.1%. This makes short-read sequencing the gold standard for detecting single-letter changes (SNPs) and small insertions or deletions — the type of variant responsible for the majority of the well-characterized disease genes covered elsewhere on this site. It's also dramatically cheaper per genome, which is exactly why it's the default choice for population-scale and consumer sequencing.

Where Short Reads Structurally Can't Compete

The genome contains long stretches of highly repetitive sequence — centromeres, telomeres, ribosomal DNA regions, and tandem repeat expansions (the exact kind of repeat responsible for conditions like Huntington's disease). When a short-read fragment lands in the middle of one of these repetitive regions, there's often no way to confidently determine exactly where it belongs, because the surrounding sequence looks identical in multiple places across the genome. Long reads, by contrast, can span the entire repetitive region in a single continuous read, resolving ambiguity that's structurally impossible for short reads to untangle.

Why "Phasing" Is a Bigger Deal Than It Sounds

Here's a scenario short-read sequencing genuinely struggles with: if you have two different pathogenic variants in the same gene, it matters enormously whether they're on the same copy of the chromosome (inherited from one parent) or on opposite copies (one from each parent). The first scenario might leave you with one fully functional gene copy; the second might mean neither copy works. Standard short-read sequencing frequently can't distinguish between these two scenarios without additional testing of your parents. Long-read sequencing can often resolve this directly, because a single long read can span both variant positions and show definitively whether they travel together.

So Should You Care, Practically Speaking?

For the majority of well-established, actionable findings — carrier status for conditions like cystic fibrosis, pharmacogenomic variants, most cancer-predisposition genes — short-read sequencing at adequate coverage remains genuinely reliable, which is exactly why it's the industry standard rather than a compromise. Long-read sequencing earns its cost premium in more specific situations:

• Unsolved rare disease cases, where short-read WGS and WES have already come back negative — long-read sequencing is increasingly used specifically to search the regions short reads can't reliably reach.
• Conditions caused by repeat expansions, like Huntington's disease, where the diagnostic mutation is structurally difficult for short reads to size accurately.
• Complex structural variant detection in general, relevant to certain cancer risk genes and structural chromosomal conditions.